Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOSTB4 fetal mesenchymal stem cell study in severe osteogenesis imperfecta
NL-OMON52466Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic expanded fetal mesenchymal stem cells in osteogenesis imperfecta (OI) and Osteogenesis imperfecta type III (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Safety and tolerability. Started Oct 2022; status: recruiting.
02
Drugs
allogeneic expanded fetal mesenchymal stem cells
03
Conditions
osteogenesis imperfecta (OI)Osteogenesis imperfecta type III
Beyond the preview
Go deeper on NL-OMON52466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52466.